![[SIGN thistle header]](../../../images/page-header-template.jpg)
1 Clinical Outcomes Working Group. Clinical outcome
indicators. Edinburgh: Clinical Resource and Audit Group; 2000. [cited 4 Nov
2002]. Available from url: http://www.show.scot.nhs.uk/indicators/Outcomes/OutcomesReport2000.pdf
![[back]](../../../images/refback.gif){kind=small}
[section 1.1] [section
1.2]
2 ISD Scotland. Cancer incidence and mortality
by site/type of cancer, sex and year of diagnosis/registration of death: 1989-1998.
Edinburgh: ISD Scotland; 2000.
3 ISD Scotland. Key health topics. Cancer. Facts
and figures. Colorectal (or large bowel) cancer.
4 Muir CS, McKinney PA. A strategy for cancer
control in Scotland. Glasgow: Scottish Forum for Public Health Medicine; 1994.
5 Berrino F, Capocaccia R, Estève J, Gatta
G, Hakulinen T, Micheli A, et al., editors. Survival of Cancer Patients in Europe:
the EUROCARE-2 Study. Lyon: International Agency for Research on Cancer; 1999.
6 Gatta G, Faivre J, Capocaccia R, Ponz de Leon
M. Survival of colorectal cancer patients in Europe during the period 1978-1989.
Eur J Cancer 1998;34:2176-83.
7 Bergström A, Pisani P, Tenet V, Wolk A,
Adami H. Overweight as an avoidable cause of cancer in Europe. Int J Cancer
2001;91:421-30.
8 Michels KB, Giovannucci E, Joshipura KJ, Rosner
BA, Stampfer MJ, Fuchs CS, et al. Prospective study of fruit and vegetable consumption
and incidence of colon and rectal cancers. J Natl Cancer Inst 2000;92:1740-52.
9 Potter J, editor. Food, nutrition and the prevention
of cancer: a global perspective. London: World Cancer Research Fund; 1997.
[section 2.1.2] [section
2.4]
10 Kim YI. AGA technical review: impact of
dietary fiber on colon cancer occurrence. Gastroenterology 2000;118:1235-57.
11 Byers T. Diet, colorectal adenomas, and
colorectal cancer. N Engl J Med 2000;342:1206-7.
12 Sandhu MS, White IR, McPherson K. Systematic
review of the prospective cohort studies on meat consumption and colorectal
cancer risk: a meta-analytical approach. Cancer Epidemiol Biomarkers Prev 2001;10:439-46.
13 Norat T, Lukanova A, Ferrari P, Riboli E.
Meat consumption and colorectal cancer risk: dose-response meta-analysis of
epidemiological studies. Int J Cancer 2002;98:241-56.
14 IARC Working Group on the Evaluation of
Cancer Preventive Agents. Carontenoids. Lyon: International Agency for Research
on Cancer; 1998.
15 Kiningham RB. Physical activity and the
primary prevention of cancer. Prim Care 1998;25:515-36.
16 Colditz GA, Cannuscio CC, Frazier AL. Physical
activity and reduced risk for colon cancer: implications for prevention. Cancer
Causes Control 1997;8:649-67.
17 Friedenreich CM. Physical activity and cancer
prevention: from observational to intervention research. Cancer Epidemiol Biomarkers
Prev 2001;10:287-301.
18 IARC Working Group on the Evaluation of
Cancer Preventive Agents. Weight control and physical activity. Lyon: International
Agency for Research on Cancer; 2002.
19 Giovannucci E. An updated review of the
epidemiological evidence that cigarette smoking increases risk of colorectal
cancer. Cancer Epidemiol Biomarkers Prev 2001;10:725-31.
20 Corrao G, Bagnardi V, Zambon A, Arico S.
Exploring the dose-response relationship between alcohol consumption and the
risk of several alcohol-related conditions: a meta-analysis. Addiction 1999;94:1551-73.
21 Crandall CJ. Estrogen replacement therapy
and colon cancer: a clinical review. J Womens Health Gen Based Med;1999:1155-66.
22 Risks and benefits of estrogen plus progestin
in healthy postmenopausal women: principal results from the Women’s Health
Initiative randomised controlled trial. JAMA 2002;288:321-33.
23 Hebert-Croteau N. A meta-analysis of hormone
replacement therapy and colon cancer in women. Cancer Epidemiol Biomarkers Prev
1998;7:653-9.
24 Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal
hormone therapy and the risk of colorectal cancer: a review and meta-analysis.
Am J Med 1999;106:574-82.
25 Beral V, Banks E, Reeves G, Appleby P. Use
of HRT and the subsequent risk of cancer. J Epidemiol Biostat 1999;4:191-215.
26 Nanda K, Bastian LA, Hasselblad V, Simel
DL. Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis.
Obstet Gynecol 1999;93:880-8.
27 Franceschi S, La Vecchia C. Colorectal cancer
and hormone replacement therapy: an unexpected finding. Eur J Cancer Prev 1998;7:427-38.
28 IARC Working Group on the Evaluation of
Cancer Preventive Agents. Non-steroidal anti-inflammatory drugs. Lyon: International
Agency for Research on Cancer; 1997.
29 Towler B, Irwig L, Glasziou P, Kewenter
J, Weller D, Silagy C. A systematic review of the effects of screening for colorectal
cancer using the faecal occult blood test, hemoccult. BMJ 1998;317:559-65.
[section 2.7.1] [section
5.1]
30 Mandel JS, Church TR, Bond JH, Ederer F,
Geisser MS, Mongin SJ, et al. The effect of fecal occult-blood screening on
the incidence of colorectal cancer. N Engl J Med 2000;343:1603-7.
[section 2.7.1] [section
2.7.3]
31 Rhodes JM. Colorectal cancer screening in
the UK: Joint position statement by the British Society of Gastroenterology,
The Royal College of Physicians, and The Association of Coloproctology of Great
Britain and Ireland. Gut 2000;46:746-8.
32 Steele RJ, Parker R, Patnick J, Warner J,
Fraser C, Mowat NA, et al. A demonstration pilot trial for colorectal cancer
screening in the United Kingdom: a new concept in the introduction of healthcare
strategies. J Med Screen 2001;8:197-202.
33 Eaden JA, Abrams KR, Mayberry JF. The risk
of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526-35.
34 Gillen CD, Walmsley RS, Prior P, Andrews
HA, Allan RN. Ulcerative colitis and Crohn’s disease: a comparison of
the colorectal cancer risk in extensive colitis. Gut 1994;35:1590-2.
35 Winawer SJ, Fletcher RH, Miller L, Godlee
F, Stolar MH, Mulrow CD, et al. Colorectal cancer screening: clinical guidelines
and rationale. Gastroenterology 1997;112:594-642.
[section 2.7.2] [section
2.7.3] [section 4.1] [section
10]
36 Bond JH. Colorectal cancer update. Prevention,
screening, treatment, and surveillance for high-risk groups. Med Clin North
Am 2000;84:1163-82.
[section 2.7.2] [section
2.7.3]
37 van Stolk RU, Beck GJ, Baron JA, Haile R,
Summers R. Adenoma characteristics at first colonoscopy as predictors of adenoma
recurrence and characteristics at follow-up. The Polyp Prevention Study Group.
Gastroenterology 1998;115:13-8.
38 Lund JN, Scholefield JH, Grainge MJ, Smith
SJ, Mangham C, Armitage NC, et al. Risks, costs, and compliance limit colorectal
adenoma surveillance: lessons from a randomised trial. Gut 2001;49:91-6.
39 Thiis-Evensen E, Wilhelmsen I, Hoff GS,
Blomhoff S, Sauar J. The psychologic effect of attending a screening program
for colorectal polyps. Scand J Gastroenterol 1999;34:103-9.
40 Wardle J, Taylor T, Sutton S, Atkin W. Does
publicity about cancer screening raise fear of cancer? Randomised trial of the
psychological effect of information about cancer screening. BMJ 1999;319:1037-8.
41 Derogatis LR, Morrow GR, Fetting J, Penman
D, Piasetsky S, Schmale AM, et al. The prevalence of psychiatric disorders among
cancer patients. JAMA. 1983;249:751-7.
42 Fallowfield L, Ratcliffe V, Jenkins V, Saul
J. Psychiatric morbidity and its recognition by doctors in patients with cancer.
Br J Cancer 2001;84:1011-5.
43 Slevin ML, Nichols SE, Downer SM, Wilson
P, Lister TA, Arnott S, et al. Emotional support for cancer patients: what do
patients really want? Br J Cancer 1996;74:1275-9.
44 Harrison J, Haddad P, Maguire P. The impact
of cancer on key relatives: a comparison of relative and patient concerns. Eur
J Cancer 1995;31A:1736-40.
45 Baider L, Koch U, Esacson R, De-Nour AK.
Prospective study of cancer patients and their spouses: the weakness of marital
strength. Psychooncology 1998;7:49-56.
46 Northouse LL, Schafer JA, Tipton J, Metivier
L. The concerns of patients and spouses after the diagnosis of colon cancer:
a qualitative analysis. J Wound Ostomy Continence Nurs 1999;26:8-17.
47 Nijboer C, Triemstra M, Tempelaar R, Sanderman
R, van den Bos GA. Determinants of caregiving experiences and mental health
of partners of cancer patients. Cancer 1999;86:577-88.
[section 3.1] [section
3.2]
48 Sprangers MAG, Taal BG, Aaronson NK, de
Velde A. Quality of life in colorectal cancer. Stoma vs nonstoma patients. Dis
Colon Rectum 1995;38:361-9.
49 Camilleri-Brennan J, Steele RJC. Quality
of life after treatment for rectal cancer. Br J Surg 1998;85:1036-43.
50 Bekkers MJ, van Knippenberg FC, van Dulmen
AM, van den Borne HW, van Berge Henegouwen GP. Survival and psychosocial adjustment
to stoma surgery and nonstoma bowel resection: a 4-year follow-up. J Psychosom
Res 1997;42:235-44.
51 Knowles G, Tierney A, Jodrell D, Cull A.
The perceived information needs of patients receiving adjuvant chemotherapy
for surgically resected colorectal cancer. Eur J Oncol Nurs 1999;13:208-22.
[section 3.1] [section
3.2]
52 Jenkins V, Fallowfield L, Saul J. Information
needs of patients with cancer: results from a large study in UK cancer centres.
Br J Cancer 2001;84:48-51.
53 Fallowfield L, Saul J, Gilligan B. Teaching
senior nurses how to teach communication skills in oncology. Cancer Nurs 2001;24:185-91.
54 Scott JT, Entwistle VA, Sowden AJ, Watt
I. Recordings or summaries of consultations for people with cancer (Cochrane
Review). In: The Cochrane Library, Issue 4, 2002. Oxford: Update Software.
55 Jones R, Pearson J, McGregor S, Cawsey A,
Barrett A, Craig N, et al. Randomised trial of personalised computer based information
for cancer patients. BMJ 1999;319:1241-7.
56 Bruera E, Pituskin E, Calder K, Neumann
CM, Hanson J. The addition of an audiocassette recording of a consultation to
written recommendations for patients with advanced cancer: a randomized, controlled
trial. Cancer 1999;86:2420-5.
57 Bekker H, Thornton JG, Airey CM, Connelly
JB, Hewison J, Robinson MB, et al. Informed decision making: an annotated bibliography
and systematic review. Health Technol Assess 1999;3:1-156. [cited 5 Nov 2002].
Available from url: http://www.hta.nhsweb.nhs.uk/fullmono/mon301.pdf
58 Beaver K, Bogg J, Luker KA. Decision-making
role preferences and information needs: a comparison of colorectal and breast
cancer. Health Expect 1999;2:266-76.
59 Scottish Cancer Co-ordinating and Advisory
Committee. Commissioning Cancer Services Sub-Committee. Interim report to the
Chief Medical Officer, SODoH. Edinburgh: The Scottish Office; 1995.
60 Clinical Standards Board for Scotland. Clinical
standards: colorectal cancer. Edinburgh: The Board; 2001. [cited 5 Nov 2002].
Available from url: http://www.clinicalstandards.org/pdf/finalstand/COLORECTAL.pdf
61 Fuchs CS, Giovannucci EL, Colditz GA, Hunter
DJ, Speizer FE, Willett WC. A prospective study of family history and the risk
of colorectal cancer. N Engl J Med. 1994;331:1669-74.
62 Scottish Cancer Group. Cancer Genetics Sub-Group.
Cancer genetics services in Scotland: guidance to support the implementation
of genetic services for breast, ovarian and colorectal cancer predisposition.
Edinburgh: The Scottish Executive; 2001. [cited 3 Jul 2002]. Available from
url: http://www.show.scot.nhs.uk/sehd/mels/HDL2001_24GuideFull.pdf
63 Kune GA, Kune S, Watson LF. The role of
heredity in the etiology of large bowel cancer: data from the Melbourne Colorectal
Cancer Study. World J Surg 1989;13:124-9.
64 Lynch HT, Kimberling W, Albano WA, Lynch
JF, Biscone K, Schuelke GS, et al. Hereditary nonpolyposis colorectal cancer
(Lynch syndromes I and II). I. Clinical description of resource. Cancer 1985;56:934-8.
65 Guillem JG, Forde KA, Treat MR, Neugut AI,
O’Toole KM, Diamond BE. Colonoscopic screening for neoplasms in asymptomatic
first-degree relatives of colon cancer patients. A controlled, prospective study.
Dis Colon Rectum 1992;35:523-9.
66 Brewer DA, Fung CL, Chapuis PH, Bokey EL.
Should relatives of patients with colorectal cancer be screened? A critical
review of the literature. Dis Colon Rectum 1994;37:1328-38.
67 Dowling DJ, St John DJ, Macrae FA, Hopper
JL. Yield from colonoscopic screening in people with a strong family history
of common colorectal cancer. J Gastroenterol Hepatol 2000;15:939-44.
68 Vasen HF, Mecklin JP, Khan PM, Lynch HT.
The International Collaborative Group on Hereditary Non-Polyposis Colorectal
Cancer (ICG-HNPCC). Dis Colon Rectum 1991;34:424-5.
69 Vasen HF, Watson P, Mecklin JP, Lynch HT.
New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC,
Lynch syndrome) proposed by the International Collaborative group on HNPCC.
Gastroenterology 1999;116:1453-6.
70 Rodriguez-Bigas MA, Boland CR, Hamilton
SR, Henson DE, Jass JR, Khan PM, et al. A National Cancer Institute Workshop
on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and
Bethesda guidelines. J Natl Cancer Inst 1997;89:1758-62.
71 Wijnen JT, Vasen HF, Khan PM, Zwinderman
AH, van der Klift H, Mulder A, et al. Clinical findings with implications for
genetic testing in families with clustering of colorectal cancer. N Engl J Med
1998;339:511-8.
72 Cravo ML, Fidalgo PO, Lage PA, Albuquerque
CM, Chaves PP, Claro I, et al. Validation and simplification of Bethesda guidelines
for identifying apparently sporadic forms of colorectal carcinoma with microsatellite
instability. Cancer 1999;85:779-85.
73 Syngal S, Fox EA, Eng C, Kolodner RD, Garber
JE. Sensitivity and specificity of clinical criteria for hereditary non- polyposis
colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet 2000;37:641-5.
74 Boland CR, Thibodeau SN, Hamilton SR, Sidransky
D, Eshleman JR, Burt RW, et al. A National Cancer Institute Workshop on Microsatellite
Instability for cancer detection and familial predisposition: development of
international criteria for the determination of microsatellite instability in
colorectal cancer. Cancer Res 1998;58:5248-57.
75 Aaltonen LA, Salovaara R, Kristo P, Canzian
F, Hemminki A, Peltomaki P, et al. Incidence of hereditary nonpolyposis colorectal
cancer and the feasibility of molecular screening for the disease. N Engl J
Med 1998;338:1481-7.
76 Vasen HF, Wijnen JT, Menko FH, Kleibeuker
JH, Taal BG, Griffioen G, et al. Cancer risk in families with hereditary nonpolyposis
colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996;110:1020-7.
[section 4.2] [section
4.3]
77 Dunlop MG, Farrington SM, Carothers AD,
Wyllie AH, Sharp L, Burn J, et al. Cancer risk associated with germline DNA
mismatch repair gene mutations. Hum Mol Genet 1997;6:105-10.
78 Bishop DT, Hall NR. The genetics of colorectal
cancer. Eur J Cancer 1994;30A:1946-56.
79 Rhodes M, Bradburn DM. Overview of screening
and management of familial adenomatous polyposis. Gut 1992;33:125-31.
80 NHS Executive. Cancer referral guidelines:
referral guidelines for suspected cancer. London: The Executive; 2000. (Health
Service circular HSC 2000/013). [cited 27 Jul 2004]. Available from url: http://www.dh.gov.uk/assetRoot/04/01/22/53/04012253.pdf
81 Fijten GH, Starmans R, Muris JW, Schouten
HJ, Blijham GH, Knottnerus JA. Predictive value of signs and symptoms for colorectal
cancer in patients with rectal bleeding in general practice. Fam Pract 1995;12:279-86.
82 Norrelund N, Norrelund H. Colorectal cancer
and polyps in patients aged 40 years and over who consult a GP with rectal bleeding.
Fam Pract 1996;13:160-5.
83 Crosland A, Jones R. Rectal bleeding: prevalence
and consultation behaviour. BMJ 1995;311:486-8. [section
5.1] [section 5.3]
84 Helfand M, Marton KI, Zimmer-Gembeck MJ,
Sox HC Jr. History of visible rectal bleeding in a primary care population.
Initial assessment and 10-year follow-up. JAMA 1997;277:44-8.
85 Stellon AJ, Kenwright SE. Iron deficiency
anaemia in general practice: presentations and investigations. Br J Clin Pract
1997;51:78-80.
86 Scottish Executive. Scottish referral guidelines
for suspected cancer. Edinburgh: The Executive; 2002. [cited 3 Jul 2002]. Available
from url: http://www.scotland.gov.uk/library5/health/rgsc.pdf
87 Potter MA, Wilson RG. Diagnostic delay in
colorectal cancer. J R Coll Surg Edinb 1999;44:313-6.
[section 5.2] [section
5.3]
88 Goodman D, Irvin TT. Delay in the diagnosis
and prognosis of carcinoma of the right colon. Br J Surg 1993;80:1327-9.
[section 5.2] [section
5.3]
89 Mor V, Masterson-Allen S, Goldberg R, Guadagnoli
E, Wool MS. Pre-diagnostic symptom recognition and help seeking among cancer
patients. J Community Health 1990;15:253-66.
90 Holliday HW, Hardcastle JD. Delay in diagnosis
and treatment of symptomatic colorectal cancer. Lancet 1979;1:309-11.
91 Carter S, Winslet M. Delay in the presentation
of colorectal carcinoma: a review of causation. Int J Colorectal Dis 1998;13:27-31.
92 Rex DK, Weddle RA, Lehman GA, Pound DC,
O’Connor KW, Hawes RH, et al. Flexible sigmoidoscopy plus air contrast
barium enema versus colonoscopy for suspected lower gastrointestinal bleeding.
Gastroenterology 1990;98:855-61.
93 Winawer SJ, Stewart ET, Zauber AG, Bond
JH, Ansel H, Waye JD, et al. A comparison of colonoscopy and double-contrast
barium enema for surveillance after polypectomy. National Polyp Study Work Group.
N Engl J Med 2000;342:1766-72.
94 de Zwart IM, Griffioen G, Shaw MP, Lamers
CB, de Roos A. Barium enema and endoscopy for the detection of colorectal neoplasia:
sensitivity, specificity, complications and its determinants. Clin Radiol 2001;56:401-9.
95 Flexible sigmoidoscopy. American Society
for Gastrointestinal Endoscopy. Gastrointest Endosc 1998;48:695-6.
96 Winnan G, Berci G, Panish J, Talbot TM,
Overholt BF, McCallum RW. Superiority of the flexible to the rigid sigmoidoscope
in routine proctosigmoidoscopy. N Engl J Med 1980;302:1011-2.
97 Rex DK, Rahmani EY, Haseman JH, Lemmel GT,
Kaster S, Buckley JS. Relative sensitivity of colonoscopy and barium enema for
detection of colorectal cancer in clinical practice. Gastroenterology 1997;112:17-23.
98 Thoeni RF, Laufer I. Polyps and cancer.
In: Gore R, Levine MS, Laufer I, editors. Textbook of gastrointestinal radiology.
Philadelphia: WB Saunders; 1994. p. 1160.
[section 6.1] [section
6.2] [section 6.3]
99 Bartram CI. The colon and rectum. In: Curati
WL, Cosgrove DO, Lipton MJ, Allison DJ, editors. Imaging in oncology. London:
Greenwich Medical Media; 1998. p. 99-110.
100 Atkin W. Implementing screening for colorectal
cancer. BMJ 1999;319:1212-3.
101 Waye JD, Kahn O, Auerbach ME. Complications
of colonoscopy and flexible sigmoidoscopy. Gastrointest Endosc Clin N Am 1996;6:343-77.
102 Kewenter J, Brevinge H, Engaras B, Haglind
E. The yield of flexible sigmoidoscopy and double-contrast barium enema in the
diagnosis of neoplasms in the large bowel in patients with a positive Hemoccult
test. Endoscopy 1995;27:159-63.
103 Blakeborough A, Sheridan MB, Chapman
AH. Complications of barium enema examinations: a survey of UK Consultant Radiologists
1992 to 1994. Clin Radiol 1997;52:142-8.
104 Connolly DJ, Traill ZC, Reid HS, Copley
SJ, Nolan DJ. The double contrast barium enema: a retrospective single centre
audit of the detection of colorectal carcinomas. Clin Radiol 2002;57:29-32.
105 Jensen J, Kewenter J, Asztely M, Lycke
G, Wojciechowski J. Double contrast barium enema and flexible rectosigmoidoscopy:
a reliable diagnostic combination for detection of colorectal neoplasm. Br J
Surg 1990;77:270-2.
106 Miao YM, Amin Z, Healy J, Burn P, Murugan
N, Westaby D, et al. A prospective single centre study comparing computed tomography
pneumocolon against colonoscopy in the detection of colorectal neoplasms. Gut
2000;47:832-7.
107 McFarland EG, Brink JA. Helical CT colonography
(virtual colonoscopy): the challenge that exists between advancing technology
and generalizability. AJR Am J Roentgenol 1999;173:549-59.
108 Stevenson GW. Colorectal cancer imaging:
a challenge for radiologists. Radiology 2000;214:615-21.
109 Heriot AG, Grundy A, Kumar D. Preoperative
staging of rectal carcinoma. Br J Surg 1999;86:17-28.
110 Knol JA, Marn CS, Francis IR, Rubin JM,
Bromberg J, Chang AE. Comparisons of dynamic infusion and delayed computed tomography,
intraoperative ultrasound and palpation in the diagnosis of liver metastases.
Am J Surg 1993;165:81-7.
111 Kwok H, Bissett IP, Hill GL. Preoperative
staging of rectal cancer. Int J Colorectal Dis 2000;15:9-20.
112 Beets-Tan RG, Beets GL, Vliegen RF, Kessels
AG, Van Boven H, De Bruine A, et al. Accuracy of magnetic resonance imaging
in prediction of tumour-free resection margin in rectal cancer surgery. Lancet
2001;357:497-504.
113 Williams NS, Jass JR, Hardcastle JD.
Clinicopathological assessment and staging of colorectal cancer. Br J Surg 1988;75:649-52.
114 Scottish Intercollegiate Guidelines Network
(SIGN). Prophylaxis of venous thromboembolism. Edinburgh: SIGN; 2002. (SIGN
publication no. 62).
115 Scottish Intercollegiate Guidelines Network
(SIGN). Antibiotic prophylaxis in surgery. Edinburgh: SIGN; 2000. (SIGN publication
no. 45).
116 Glenny AM, Song F. Antimicrobial prophylaxis
in colorectal surgery. Qual Health Care 1999;8:132-6.
117 Burke P, Mealy K, Gillen P, Joyce W,
Traynor O, Hyland J. Requirement for bowel preparation in colorectal surgery.
Br J Surg 1994;81:907-10.
118 Santos JC Jr, Batista J, Sirimarco MT,
Guimaraes AS, Levy CE. Prospective randomized trial of mechanical bowel preparation
in patients undergoing elective colorectal surgery. Br J Surg 1994;81:1673-6.
119 Miettinen RP, Laitinen ST, Makela JT,
Paakkonen ME. Bowel preparation with oral polyethylene glycol electrolyte solution
vs. no preparation in elective open colorectal surgery: prospective, randomized
study. Dis Colon Rectum 2000;43:669-75.
120 Foster RS, Costanza MC, Foster JC, Wanner
MC, Foster CB. Adverse relationship between blood transfusions and survival
after colectomy for colon cancer. Cancer 1985;55:1195-201.
121 McAlister FA, Clark HD, Wells PS, Laupacis
A. Perioperative allogeneic blood transfusion does not cause adverse sequelae
in patients with cancer: a meta-analysis of unconfounded studies. Br J Surg
1998;85:171-8.
122 Heald RJ, Moran BJ, Ryall RD, Sexton
R, MacFarlane JK. Rectal cancer: the Basingstoke experience of total mesorectal
excision, 1978-1997. Arch Surg 1998;133:894-9.
123 Wiig JN, Carlsen E, Soreide O. Mesorectal
excision for rectal cancer: a view from Europe. Semin Surg Oncol 1998;15:78-86.
124 Martling AL, Holm T, Rutqvist LE, Moran
BJ, Heald RJ, Cedemark B. Effect of a surgical training programme on outcome
of rectal cancer in the County of Stockholm. Stockholm Colorectal Cancer Study
Group, Basingstoke Bowel Cancer Research Project. Lancet 2000;356:93-6.
[section 7.4.1] [section
7.9]
125 Adam IJ, Mohamdee MO, Martin IG, Scott
N, Finan PJ, Johnston D, et al. Role of circumferential margin involvement in
the local recurrence of rectal cancer. Lancet 1994;344:707-11.
126 Lewis WG, Martin IG, Williamson ME, Stephenson
BM, Holdsworth PJ, Finan PJ, et al. Why do some patients experience poor functional
results after anterior resection of the rectum for carcinoma? Dis Colon Rectum
1995;38:259-63.
127 Havenga K, Maas CP, DeRuiter MC, Welvaart
K, Trimbos JB. Avoiding long-term disturbance to bladder and sexual function
in pelvic surgery, particularly with rectal cancer. Semin Surg Oncol 2000;18:235-43.
128 Wiggers T, Jeekel J, Arends JW, Brinkhorst
AP, Kluck HM, Luyk CI. No-touch isolation technique in colon cancer: a controlled
prospective trial. Br J Surg 1988;75:409-15.
129 Rouffet F, Hay JM, Vacher B, Fingerhut
A, Elhadad A, Flamant Y, et al. Curative resection for left colonic carcinoma:
hemicolectomy vs. segmental colectomy. A prospective, controlled, multicenter
trial. French Association for Surgical Research. Dis Colon Rectum 1994;37:651-9.
130 MacRae HM, McLeod RS. Handsewn vs. stapled
anastomoses in colon and rectal surgery: a meta- analysis. Dis Colon Rectum
1998;41:180-9.
131 Rullier E, Laurent C, Garrelon JL, Michel
P, Saric J, Parneix M. Risk factors for anastomotic leakage after resection
of rectal cancer. B J Surg 1998;85:355-8.
132 Dehni N, Schlegel RD, Cunningham C, Guiguet
M, Tiret E, Parc R. Influence of a defunctioning stoma on leakage rates after
low colorectal anastomosis and colonic J pouch-anal anastomosis. Br J Surg 1998;85:1114-7.
133 Williams N, Seow-Choen F. Physiological
and functional outcome following ultra-low anterior resection with colon pouch-anal
anastomosis. Br J Surg 1998;85:1029-35.
134 Huber FT, Herter B, Siewert JR. Colonic
pouch vs. side-to-end anastomosis in low anterior resection. Dis Colon Rectum
1999;42:896-902.
135 Ho YH, Tan M, Leong A, Seow-Choen F.
Ambulatory manometry in patients with colonic J-pouch and straight coloanal
anastomoses: randomized, controlled trial. Dis Colon Rectum 2000;43:793-9.
136 Winde G, Nottberg H, Keller R, Schmid
KW, Bunte H. Surgical cure for early rectal carcinomas (T1). Transanal endoscopic
microsurgery vs. anterior resection. Dis Colon Rectum 1996;39:969-76.
137 Breen E, Bleday R. Preservation of the
anus in the therapy of distal rectal cancers. Surg Clin North Amer 1997;77:71-83.
138 Kikuchi R, Takano M, Takagi K, Fujimoto
N, Nozaki R, Fujiyoshi T, et al. Management of early invasive colorectal cancer.
Risk of recurrence and clinical guidelines. Dis Colon Rectum 1995;38:1286-95.
139 Wolff WL, Shinya H, Cwern M, Hsu M. Cancerous
colonic polyps. “Hands on” or “hands off?”. Am Surg
1990;56:148-52.
140 Chapman MAS, Scholefield JH, Hardcastle
JD. Management and outcome of patients with malignant colonic polyps identified
from the Nottingham Colorectal Screening Study. Colorectal Dis 2000;2:8-12.
141 Maxwell-Armstrong CA, Robinson MH, Scholefield
JH. Laparoscopic colorectal cancer surgery. Am J Surg 2000;179:500-7.
142 Koruth NM, Koruth A, Matheson NA. The
place of contrast enema in the management of large bowel obstruction. J R Coll
Surg Edinb 1985;30:258-60.
143 Deans GT, Krukowski ZH, Irwin ST. Malignant
obstruction of the left colon. Br J Surg 1994;81:1270-6.
144 Single-stage treatment for malignant
left-sided colonic obstruction: a prospective randomized clinical trial comparing
subtotal colectomy with segmental resection following intraoperative irrigation.
The SCOTIA Study Group. Subtotal Colectomy versus On-table Irrigation and Anastomosis.
Br J Surg 1995;82:1622-7.
145 Lo SK. Metallic stenting for colorectal
obstruction. Gastrointest Endosc Clin N Am 1999;9:459-77.
146 Camunez F, Echenagusia A, Simo G, Turegano
F, Vazquez J, Barreiro-Meiro I. Malignant colorectal obstruction treated by
means of self-expanding metallic stents: effectiveness before surgery and in
palliation. Radiology 2000; 216:492-7.
147 Scheele J, Stang R, Altendorf-Hofmann
A, Paul M. Resection of colorectal liver metastases. World J Surg 1995;19:59-71.
148 Shirouzu K, Isomoto H, Hayashi A, Nagamatsu
Y, Kakegawa T. Surgical treatment for patients with pulmonary metastases after
resection of primary colorectal carcinoma. Cancer 1995;76:393-8.
149 Seifert JK, Junginger T, Morris DL. A
collective review of the world literature on hepatic cryotherapy. J R Coll Surg
Edinb 1998;43:141-54.
150 Sagar PM, Pemberton JH. Surgical management
of locally recurrent rectal cancer. Br J Surg 1996;83:293-304.
151 Dohmoto M, Hunerbein M, Schlag PM. Palliative
endoscopic therapy of rectal carcinoma. Eur J Cancer 1996;32A:25-9.
152 Hillner BE, Smith TJ, Desch CE. Hospital
and physician volume or specialization and outcomes in cancer treatment: importance
in quality of cancer care. J Clin Oncol 2000;18:2327-40.
153 Meagher AP. Colorectal cancer: is the
surgeon a prognostic factor? A systematic review. Med J Austr 1999;171:308-10.
154 Shepherd NA, Baxter KJ, Love SB. The
prognostic importance of peritoneal involvement in colonic cancer: A prospective
evaluation. Gastroenterology 1997;112:1096-102.
155 Talbot IC, Ritchie S, Leighton MH, Hughes
AO, Bussey HJR, Morson BC. The clinical significance of invasion of veins by
rectal cancer. Br J Surg 1980; 67:439-42.
156 Adam IJ, Mohamdee MO, Martin IG, Scott
N, Finan PJ, Johnston D, et al. Role of circumferential margin involvement in
the local recurrence of rectal cancer. Lancet 1994;344:707-11.
157 Cross SS, Feeley KM, Angel CA. The effect
of four interventions on the informational content of histopathology reports
of resected colorectal carcinomas. J Clin Pathol 1998;51:481-2.
158 Branston LK, Greening S, Newcombe RG,
Daoud R, Abraham JM, Wood F, et al. The implementation of guidelines and computerised
forms improves the completeness of cancer pathology reporting. The CROPS project:
a randomised controlled trial in pathology. Eur J Cancer 2002;38:764-72.
159 Joint Council for Clinical Oncology.
Quality control in cancer chemotherapy: managerial and procedural aspects. London:
Royal College of Physicians. Royal College of Radiologists; 1994.
160 Scottish Executive Health Department.
Guidelines for the use of cytotoxic chemotherapy in the clinical environment.
Edinburgh: The Department; 2001. (NHS HDL (2001)13). [cited 3 Jul 2002]. Available
from url: http://www.show.scot.nhs.uk/sehd/mels/HDL2001_13.htm
161 Figueredo A, Fine S, Maroun J, Walker-Dilks
C, Wong S. Adjuvant therapy for stage III colon cancer after complete resection.
Cancer Prev Control 1997; 1:304-19.
[section 9.1] [section
9.1.3]
162 O’Connell MJ, Mailliard JA, Kahn
MJ, Macdonald JS, Haller DG, Mayer RJ, et al. Controlled trial of fluorouracil
and low-dose leucovorin given for 6 months as postoperative adjuvant therapy
for colon cancer. J Clin Oncol 1997; 15:246-50.
[section 9.1] [section
9.1.3]
163 Efficacy of adjuvant fluorouracil and
folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon
Cancer Trials (IMPACT) investigators. Lancet 1995;345:939-44.
164 Dube S, Heyen F, Jenicek M. Adjuvant chemotherapy
in colorectal carcinoma: results of a meta-analysis. Dis Colon Rectum 1997;40:35-41.
165 Comparison of flourouracil with additional
levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for
colorectal cancer: a randomised trial. QUASAR Collaborative Group. Lancet 2000;355:1588-96.
166 Harris V, Sandridge AL, Black RJ, Brewster
DH, Gould A. Cancer registration statistics Scotland 1986-1995. Edinburgh:
ISD
Scotland Publications; 1998.
167 Figueredo A, Germond C, Maroun J, Browman
G, Walker-Dilks C, Wong S. Adjuvant therapy for stage II colon cancer after
complete resection. Provincial Gastrointestinal Disease Site Group. Cancer Prev
Control 1997;1:379-92.
168 Portal vein chemotherapy for colorectal
cancer: a meta-analysis of 4000 patients in 10 studies. Liver Infusion Meta-analysis
Group. J Natl Cancer Inst 1997;89:497-505.
169 Long-term results of single course of
adjuvant intraportal chemotherapy for colorectal cancer. Swiss Group for Clinical
Cancer Research (SAKK). Lancet 1995;345:349-53.
170 Rougier P, Sahmoud T, Nitti D, Curran
D, Doci R, De Waele B, et al. Adjuvant portal-vein infusion of fluorouracil
and heparin in colorectal cancer: a randomised trial. European Organisation
for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative
Group, the Gruppo Interdisciplinare Valutazione Interventi in Oncologia, and
the Japanese Foundation for Cancer Research. Lancet 1998;351:1677-81.
171 James RD. AXIS: intraportal 5FU and peri-operative
radiotherapy in the adjuvant treatment of colorectal cancer - results of the
UKCCCR trial. Br J Cancer 1999;80(Suppl 2):20.
172 Scheithauer W, Kornek GV, Marczell A,
Karner J, Salem G, Greiner R, et al. Combined intravenous and intraperitoneal
chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for
adjuvant therapy of resected colon carcinoma. Br J Cancer 1998;77:1349 54.
173 Riethmuller G, Holz E, Schlimok G, Schmiegel
W, Raab R, Hoffken K, et al. Monoclonal antibody therapy for resected Dukes’
C colorectal cancer: seven-year outcome of a multicenter randomized trial. J
Clin Oncol 1998;16:1788-94.
174 Punt CJ, Nagy A, Douillard JY, Figer
A, Skovsgaard T, Monson J, et al. Edrecolomab (17-1A Antibody) alone or in combination
with 5-fluorouracil based chemotherapy in the adjuvant treatment of stage III
colon cancer: results of a phase III study [abstract]. ASCO Abstracts 2001;20:Abstract
487.
175 Seymour MT, Slevin ML, Kerr DJ, Cunningham
D, James RD, Ledermann JA, et al. Randomized trial assessing the addition of
interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer.
Colorectal Cancer Working Party of the United Kingdom Medical Research Council.
J Clin Oncol 1996;14:2280-8.
[section 9.1.2] [section
9.3.6]
176 Hill M, Norman A, Cunningham D, Findlay
M, Watson M, Nicolson V, et al. Impact of protracted venous infusion fluorouracil
with or without interferon alfa-2b on tumour response, survival, and quality
of life in advanced colorectal cancer. J Clin Oncol 1995;13:2317-23.
[section 9.1.2] [section
9.3.6]
177 Wolmark N, Rockette H, Mamounas E, Jones
J, Wieand S, Wickerham DL, et al. Clinical trial to assess the relative efficacy
of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil,
leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of
the colon: results from National Surgical Adjuvant Breast and Bowel Project
C-04. J Clin Oncol 1999;17:3553-9.
178 Harris JE, Ryan L, Hoover HC Jr, Stuart
RK, Oken MM, Benson AB 3rd, et al. Adjuvant active specific immunotherapy for
stage II and III colon cancer with an autologous tumor cell vaccine: Eastern
Cooperative Oncology Group Study E5283. J Clin Oncol 2000;18:148-57.
179 Comparison of flourouracil with additional
levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for
colorectal cancer: a randomised trial. QUASAR Collaborative Group. Lancet 2000;355:1588-96.
180 Kerr DJ, Gray R, McConkey C, Barnwell
J. Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole
for patients with colorectal cancer: non-randomised comparison of weekly versus
four-weekly schedules—less pain, same gain. QUASAR Colorectal Cancer Study
Group. Ann Oncol 2000;11:947-55.
181 Saini A, Cunningham D, Norman AR, Hill
ME, Tait D, Hickish T, et al. Multicentre randomized trial of protracted venous
infusion (PVI) 5 FU compared to 5 FU/folinic acid (5FU/FA) as adjuvant therapy
for colorectal cancer [abstract]. ASCO Abstracts 2000;19:Abstract 928.
182 Hoff PM, Ansari R, Batist G, Cox J, Kocha
W, Kuperminc M, et al. Comparison of oral capecitabine versus intravenous fluorouracil
plus leucovorin as first-line treatment in 605 patients with metastatic colorectal
cancer: results of a randomized phase III study. J Clin Oncol 2001;19:2282-92.
[section 9.1.3] [section
9.3.2]
183 Camma C, Giunta M, Fiorica F, Pagliaro
L, Craxi A, Cottone M. Preoperative radiotherapy for resectable rectal cancer:
a meta-analysis. JAMA 2000;284:1008-15.
184 Munro AJ, Bentley AHM. Adjuvant radiotherapy
in operable rectal cancer: a systematic review. Semin Colon Rectal Surg 2002;13:31-42.
185 Improved survival with preoperative radiotherapy
in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med 1997;336:980-7.
186 Dahlberg M, Glimelius B, Graf W, Pahlman
L. Preoperative irradiation affects functional results after surgery for rectal
cancer: results from a randomized study. Dis Colon Rectum 1998;41:543-9.
187 Adjuvant radiotherapy for rectal cancer:
a systematic overview of 8507 patients from 22 randomised trials. Lancet 2001;358:1291-304.
188 Cedermark B, Johansson H, Rutqvist LE,
Wilking N. The Stockholm I trial of preoperative short term radiotherapy in
operable rectal carcinoma. A prospective randomized trial. Stockholm Colorectal
Cancer Study Group. Cancer 1995;75:2269-75.
189 Holm T, Singnomklao T, Rutqvist LE, Cedermark
B. Adjuvant preoperative radiotherapy in patients with rectal carcinoma. Adverse
effects during long term follow-up of two randomized trials. Cancer 1996;78:968-76.
190 Kapiteijn E, Marijnen CA, Nagtegaal ID,
Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with
total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345:638-46.
191 Frykholm GJ, Glimelius B, Pahlman L. Preoperative
or postoperative irradiation in adenocarcinoma of the rectum: final treatment
results of a randomized trial and an evaluation of late secondary effects. Dis
Colon Rectum 1993;36:564-72.
192 Glimelius B, Isacsson U, Jung B, Pahlman
L. Radiotherapy in addition to radical surgery in rectal cancer: evidence for
a dose-response effect favoring preoperative treatment. Int J Radiat Oncol Biol
Phys 1997;37:281-7.
193 Bosset JF, Pavy JJ, Hamers HP, Horiot
JC, Fabri MC, Rougier P, et al. Determination of the optimal dose of 5-fluorouracil
when combined with low dose D,L-leucovorin and irradiation in rectal cancer:
results of three consecutive phase II studies. EORTC Radiotherapy Group. Eur
J Cancer 1993;29A:1406-10.
194 Rich TA, Skibber JM, Ajani JA, Buchholz
DJ, Cleary KR, Dubrow RA, et al. Preoperative infusional chemoradiation therapy
for stage T3 rectal cancer. Int J Radiat Oncol Biol Phys 1995;32:1025-9.
195 Kapiteijn E, Marijnen CA, Nagtegaal ID,
Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with
total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345:638-46.
196 Quirke P, Durdey P, Dixon MF, Williams
NS. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection.
Histopathological study of lateral tumour spread and surgical excision. Lancet
1986;2:996-9.
197 Randomised trial of surgery alone versus
radiotherapy followed by surgery for potentially operable locally advanced rectal
cancer. Medical Research Council Rectal Cancer Working Party. Lancet 1996;348:1605-10.
198 Marsh PJ, James RD, Schofield PF. Adjuvant
preoperative radiotherapy for locally advanced rectal carcinoma. Results of
a prospective, randomized trial. Dis Colon Rectum 1994;37:1205-14.
199 Simmonds PC. Palliative chemotherapy
for advanced colorectal cancer: systematic review and meta-analysis. Colorectal
Cancer Collaborative Group. BMJ 2000;321:531-5.
[section 9.3] [section
9.3.1]
200 Jonker DJ, Maroun JA, Kocha W. Survival
benefit of chemotherapy in metastatic colorectal cancer: a meta-analysis of
randomized controlled trials. Br J Cancer 2000;82:1789-94.
[section 9.3] [section
9.3.1]
201 Cunningham D, Zalcberg JR, Rath U, Olver
I, Van Cutsem E, Svensson C, et al. ‘Tomudex’ (ZD1694): results
of a randomised trial in advanced colorectal cancer demonstrate efficacy and
reduced mucositis and leucopenia. The ‘Tomudex’ Colorectal Cancer
Study Group. Eur J Cancer 1995; 31A:1945-54.
202 de Gramont A, Bosset JF, Milan C, Rougier
P, Bouche O, Etienne PL, et al. Randomized trial comparing monthly low-dose
leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil
bolus plus continuous infusion for advanced colorectal cancer: a French intergroup
study. J Clin Oncol 1997;15:808-15.
203 Cocconi G, Cunningham D, Van Cutsem E,
Francois E, Gustavsson B, van Hazel G, et al. Open, randomized, multicenter
trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients
with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. J Clin
Oncol 1998;16:2943-52.
204 Pazdur R, Douillard JY, Skillings JR,
Eisenberg PD, Davidson N, Harper P, et al. Multicenter phase III study of 5-fluorouracil
(5-FU) or UFTTM in combination with leucovorin (LV) in patients with metastatic
colorectal cancer [abstract]. ASCO Abstracts 1999;18:Abstract 1009.
205 Efficacy of intravenous continuous infusion
of flourouracil compared with bolus administration in advanced colorectal cancer.
Meta-analysis Group in Cancer. J Clin Oncol 1998;16:301-8.
206 Lokich JJ, Ahlgren JD, Gullo JJ, Philips
JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil
with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic
Oncology Program Study. J Clin Oncol 1989;7:425-32.
207 de Gramont A, Bosset JF, Milan C, Rougier
P, Bouche O, Etienne PL, et al. Randomized trial comparing monthly low-dose
leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil
bolus plus continuous infusion for advanced colorectal cancer: a French intergroup
study. J Clin Oncol 1997;15:808-15.
208 Zalcberg J. Overview of the tolerability
of ‘Tomudex’ (raltitrexed): collective clinical experience in advanced
colorectal cancer. Anticancer Drugs 1997;8:S17-22.
209 Cunningham D. Mature results from three
large controlled studies with raltitrexed (‘Tomudex’). Br J Cancer
1998;77:15-21.
210 Stephens RJ, Hopwood P, Johnston C, Maughan
TS. The value of quality of life (QL) outcomes in comparing 3 chemotherapy regimens
(de Gramont, lokich and raltitrexed) in a multicentre randomised trial of metastatic
colorectal cancer [abstract]. ASCO Abstracts 1999;18:Abstract 2220.
211 Drug-company decision to end cancer trial.
Lancet 1999;354:1045.
212 Judson I, Maughan T, Beale P, Primrose
J, Hoskin P, Hanwell J, et al. Effects of impaired renal function on the pharmacokinetics
of raltitrexed (Tomudex ZD1694). Br J Cancer 1998;78:1188-93.
213 Köhne CH, Thuss-Patience P, Friedrich
M, Daniel PT, Kretzschmar A, Benter T, et al. Raltitrexed (Tomudex): an alternative
drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity.
Br J Cancer 1998; 77:973-7.
214 Maughan TS, James RD, Kerr DJ, Ledermann
JA, McArdle C, Seymour MT, et al. Comparison of survival, palliation, and quality
of life with three chemotherapy regimens in metastatic colorectal cancer: a
multicentre randomised trial. Lancet 2002;359:1555-63.
215 Carmichael J, Popiela T, Radstone D,
Falk S, Fey M, Oza A, et al. Randomized comparative study of ORZEL(r) (oral
uracil/tegafur (UFTTM) plus leucovorin (LV)) versus parenteral 5-fluorouracil
(5-FU) plus LV in patients with metastatic colorectal cancer [abstract]. ASCO
Abstracts 1999;18:Abstract 1015.
216 Health Technology Board for Scotland.
The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced
colorectal cancer. Understanding HTBS advice. Glasgow: The Board; 2002. [cited
27 Jul 2004]. Available from url: http://docs.scottishmedicines.org/docs/pdf/HTBS%20ADVICE-COLORECTAL%20A5.pdf
217 Saltz LB, Cox JV, Blanke C, Rosen LS,
Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin
for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-14.
218 Douillard JY, Cunningham D, Roth AD,
Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil
compared with fluorouracil alone as first-line treatment for metastatic colorectal
cancer: a multicentre randomised trial. Lancet 2000;355:1041-7.
219 Giacchetti S, Perpoint B, Zidani R, Le
Bail N, Faggiuolo R, Focan C, et al. Phase III multicenter randomized trial
of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line
treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136-47.
220 de Gramont A, Figer A, Seymour M, Homerin
M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin
as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47.
221 Ross P, Norman A, Cunningham D, Webb
A, Iveson T, Padhani A, et al. A prospective randomised trial of protracted
venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal
cancer. Ann Oncol 1997;8:995-1001.
222 Adam R, Avisar E, Ariche A, Giachetti
S, Azoulay D, Castaing D, et al. Five-year survival following hepatic resection
after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001;8:347-53.
223 Harmantas A, Rotstein LE, Langer B. Regional
versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic
to the liver. Is there a survival difference? Meta-analysis of the published
literature. Cancer 1996; 78:1639-45.
224 Reappraisal of hepatic arterial infusion
in the treatment of nonresectable liver metastases from colorectal cancer. Meta-Analysis
Group in Cancer. J Natl Cancer Inst 1996;88:252-8.
225 Lorenz M, Muller HH. Randomized, multicenter
trial of fluorouracil plus leucovorin administered either via hepatic arterial
or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial
infusion in patients with nonresectable liver metastases from colorectal carcinoma.
J Clin Oncol 2000;18:243-54.
226 Kemeny N, Huang Y, Cohen AM, Shi W, Conti
JA, Brennan MF, et al. Hepatic arterial infusion of chemotherapy after resection
of hepatic metastases from colorectal cancer. N Engl J Med 1999;341:2039-48.
227 Cunningham D, Pyrhonen S, James RD, Punt
CJ, Hickish TF, Heikkila R, et al. Randomised trial of irinotecan plus supportive
care versus supportive care alone after fluorouracil failure for patients with
metastatic colorectal cancer. Lancet 1998;352:1413-8.
228 Rougier P, Van Cutsem E, Bajetta E, Niederle
N, Possinger K, Labianca R, et al. Randomised trial of irinotecan versus fluorouracil
by continuous infusion after fluorouracil failure in patients with metastatic
colorectal cancer. Lancet 1998;352:1407-12.
229 Maxwell-Armstrong CA, Durrant LG, Buckley
TJD, Scholefield JH, Robins RA, Fielding K, et al. Randomized double-blind phase
II survival study comparing immunization with the anti-idiotypic monoclonal
antibody 105AD7 against placebo in advanced colorectal cancer. Br J Cancer 2001:84;1443-6.
230 Levi F, Zidani R, Misset JL. Randomised
multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic
acid in metastatic colorectal cancer. International Organization for Cancer
Chronotherapy. Lancet 1997; 350:681-6.
231 Habr-Gama A, de Souza PM, Ribeiro U Jr,
Nadalin W, Gansl R, Sousa AH Jr, et al. Low rectal cancer: impact of radiation
and chemotherapy on surgical treatment. Dis Colon Rectum 1998;41:1087-96.
232 Chari RS, Tyler DS, Anscher MS, Russell
L, Clary BM, Hathorn J, et al. Preoperative radiation and chemotherapy in the
treatment of adenocarcinoma of the rectum. Ann Surg 1995;221:778-87.
233 Minsky BD, Cohen AM, Kemeny N, Enker
WE, Kelsen DP, Reichman B, et al. Enhancement of radiation-induced downstaging
of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy. J Clin
Oncol 1992;10:79-84.
234 Bosset JF, Magnin V, Maingon P, Mantion
G, Pelissier EP, Mercier M, et al. Preoperative radiochemotherapy in rectal
cancer: long-term results of a phase II trial. Int J Radiat Oncol Biol Phys
2000;46:323-7.
235 Ngan SY, Burmeister BH, Fisher R, Rischin
D, Schache DJ, Kneebone A, et al. Early toxicity from preoperative radiotherapy
with continuous infusion 5-fluorouracil for resectable adenocarcinoma of the
rectum: a Phase II trial for the Trans-Tasman Radiation Oncology Group. Int
J Radiat Oncol Biol Phys 2001;50:883-7.
236 Janjan NA, Crane C, Feig BW, Cleary K,
Dubrow R, Curley S, et al. Improved overall survival among responders to preoperative
chemoradiation for locally advanced rectal cancer. Am J Clin Oncol 2001;24:107-12.
237 Spanos WJJ, Perez CA, Marcus S, Poulter
CA, Doggett RL, Steinfeld AD, et al. Effect of rest interval on tumour and normal
tissue response - a report of phase III study of accelerated split course palliative
radiation for advanced pelvic malignancies (RTOG-8502). Int J Radiat Oncol Biol
Phys 1993;25:399-403.
238 Schoemaker D, Black R, Giles L, Toouli
J. Yearly colonoscopy, liver CT, and chest radiography do not influence 5- year
survival of colorectal cancer patients. Gastroenterology 1998;114:7-14.
239 Pietra N, Sarli L, Costi R, Ouchemi C,
Grattarola M, Peracchia A. Role of follow-up in management of local recurrences
of colorectal cancer: A prospective, randomized study. Dis Colon Rectum 1998;41:1127-33.
240 Kjeldsen BJ, Kronborg O, Fenger C, Jorgensen
OD. A prospective randomized study of follow-up after radical surgery for colorectal
cancer. Br J Surg 1997;84:666-9.
241 Audisio RA, Setti-Carraro P, Segala M,
Capko D, Andreoni B, Tiberio G. Follow-up in colorectal cancer patients: a cost-benefit
analysis. Ann Surg Oncol 1996;3:349-57.
242 Secco GB, Fardelli R, Rovida S, Gianquinto
D, Baldi E, Bonfante P, et al. Is intensive follow-up really able to improve
prognosis of patients with local recurrence after curative surgery for rectal
cancer? Ann Surg Oncol 2000; 7:32-7.
243 Rosen M, Chan L, Beart RW Jr, Vukasin
P, Anthone G. Follow-up of colorectal cancer: a meta-analysis. Dis Colon Rectum
1998;41:1116-26.
244 Renehan AG, Egger ME, Saunders MP, O’Dwyer
ST. Impact on survival of intensive follow-up after curative resection for colorectal
cancer: systematic review and meta-analysis of randomised trials. BMJ 2002;324:1-8.
245 Jeffery GM, Hickey BE, Hider P. Follow-up
strategies for patients treated for non-metastatic colorectal cancer (Cochrane
Review). In: The Cochrane Library, Issue 1, 2002. Oxford: Update Software.
246 Pietra N, Sarli L, Costi R, Ouchemi C,
Grattarola M, Peracchia A. Role of follow-up in management of local recurrences
of colorectal cancer: a prospective, randomized study. Dis Colon Rectum 1998;41:1127-33.
247 McCarthy EP, Phillips RS, Zhong Z, Drews
RE, Lynn J. Dying with cancer: patients’ function, symptoms and care preferences
as death approaches. J Am Geriatr Soc 2000;48:S110-21.
248 Twycross R, Wilcock A. Symptom management
in advanced cancer. 3rd ed. Abingdon: Radcliffe Medical Press; 2001.
249 Portenoy RK, Thaler HT, Kornblith AB,
Lepore JM, Friedlander-Klar H, Coyle N, et al. Symptom prevalence, characteristics
and distress in a cancer population. Qual Life Res 1994;3:183-9.
250 Scottish Executive Health Department.
Scottish national audit of the prevalence of pain in patients with active cancers
recognised to cause pain. Edinburgh; Cancer in Scotland: 2003. [cited 6 Mar
2003] .Available from url: http://www.show.scot.nhs.uk/sehd/cancerinscotland
251 Scottish Intercollegiate Guidelines Network
(SIGN). Control of pain in patients with cancer. Edinburgh: SIGN; 2000. (SIGN
publication no. 44).
252 Ripamonti C, Twycross R, Baines M, Bozzetti
F, Capri S, De Conno F, et al. Clinical-practice recommendations for the management
of bowel obstruction in patients with end-stage cancer. Support Care Cancer
2001;9:223-33.
253 Feuer DJ, Broadley KE. Corticosteroids
for the resolution of malignant bowel obstruction in advanced gynaecological
and gastrointestinal cancer (Cochrane Review). In: The Cochrane Library, Issue
1, 2002. Oxford: Update Software.
254 Stone P, Richardson A, Ream E, Smith
AG, Kerr DJ, Kearney N. Cancer-related fatigue: inevitable, unimportant and
untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum.
Ann Oncol 2000;11:971-5.
255 Bruera E, Ernst S, Hagen N, Spachynski
K, Belzile M, Hanson J, et al. Effectiveness of megestrol acetate in patients
with advanced cancer: a randomized, double-blind, crossover study. Cancer Prev
Control 1998;2:74-8.
256 Fearon KC, Barber MD, Moses AG. The cancer
cachexia syndrome. Surg Oncol Clin N Am 2001;10:109-26.
![[Contents]](../../../images/contents.gif){kind=small}
![[Back]](../../../images/back.gif){kind=small}
![[Top]](../../../images/top.gif){kind=small}